Thanks for posting that report by David Lebowitz at Morgan Stanley. I see they still have a relatively low price target.
ALNY: Our Alnylam price target of $93 is based on a DCF model that is driven by patisiran for hATTR-PN as well as the remaining pipeline. Our DCF projects cash flows through 2033,uses a 12.5% discount rate and a 2% terminal growth rate. Key risks include news flow regarding either successes or failures from Alnylam's pipeline could lead to swings in share value; data from Alnylam's pipeline that alters the efficacy and/or safety profile of the company's developmental drug candidates;and clinical data from competitive programs that alter the competitive dynamics of markets that Alnylam is currently pursuing.